The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | AVANA: preoperative chemo-RT plus avelumab in locally advanced rectal cancer
Lisa Salvatore, MD, MS, University and Hospital Trust of Verona, Verona, Italy, discusses the findings of a Phase II study of preoperative chemoradiotherapy plus avelumab in patients with locally advanced rectal cancer. The results of the AVANA study highlight that preoperative chemoradiotherapy (chemo-RT) plus avelumab demonstrates promising activity and a feasible safety profile. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
